These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 12482795)

  • 1. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.
    Sumitomo N; Harada K; Nagashima M; Yasuda T; Nakamura Y; Aragaki Y; Saito A; Kurosaki K; Jouo K; Koujiro M; Konishi S; Matsuoka S; Oono T; Hayakawa S; Miura M; Ushinohama H; Shibata T; Niimura I
    Heart; 2003 Jan; 89(1):66-70. PubMed ID: 12482795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
    Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
    Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T
    Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
    Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
    Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S
    Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
    Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
    Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical challenges in the management of catecholaminergic polymorphic ventricular tachycardia in children].
    Ge HY; Li XM; Jiang H; Zhang Y; Liu HJ; Zheng XC; Li MT
    Zhonghua Er Ke Za Zhi; 2017 Dec; 55(12):926-931. PubMed ID: 29262473
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronotropic incompetence as a risk predictor in children and young adults with catecholaminergic polymorphic ventricular tachycardia.
    Franciosi S; Roston TM; Perry FKG; Knollmann BC; Kannankeril PJ; Sanatani S
    J Cardiovasc Electrophysiol; 2019 Oct; 30(10):1923-1929. PubMed ID: 31231889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
    Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
    Roston TM; Vinocur JM; Maginot KR; Mohammed S; Salerno JC; Etheridge SP; Cohen M; Hamilton RM; Pflaumer A; Kanter RJ; Potts JE; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Kannankeril PJ; Sanatani S
    Circ Arrhythm Electrophysiol; 2015 Jun; 8(3):633-42. PubMed ID: 25713214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Claudio B; Alice M; Daniel S
    Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.
    van der Werf C; Zwinderman AH; Wilde AA
    Europace; 2012 Feb; 14(2):175-83. PubMed ID: 21893508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholaminergic polymorphic ventricular tachycardia.
    Ylänen K; Poutanen T; Hiippala A; Swan H; Korppi M
    Eur J Pediatr; 2010 May; 169(5):535-42. PubMed ID: 20143088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia.
    Inoue YY; Aiba T; Kawata H; Sakaguchi T; Mitsuma W; Morita H; Noda T; Takaki H; Toyohara K; Kanaya Y; Itoi T; Mitsuhashi T; Sumitomo N; Cho Y; Yasuda S; Kamakura S; Kusano K; Miyamoto Y; Horie M; Shimizu W
    Europace; 2018 Oct; 20(10):1675-1682. PubMed ID: 29309601
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.